<DOC>
	<DOC>NCT00978237</DOC>
	<brief_summary>Eligible HIV-infected patients with clinically evident lipoatrophy despite treatment with efavirenz and fixed-dose combination of thymidine nucleoside analogues will be informed and asked to enroll in the study; will be randomized (1:1) into two branches, A: EFV + Fixed combinations of analogue tenofovir + emtricitabine.B (experimental): LPV/r + combination of correspondent analogues. The main variable is the evaluation of the absolute change in limb fat mass at 24 months from baseline in both groups.</brief_summary>
	<brief_title>Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Patients HIV positive &gt; 18 years. Patients in treatment with Sustiva(r)+Truvada(r); or Sustiva (r)+Kivexa(r). HIVARN &lt; 50 copies/mL in the las six months. Clinically evident lipoatrophy (moderate or severe). Negative pregnancy test. Signed informed consent. Evidence of failure or mutation to therapy with protease inhibitors. Patients that can not be treated with LPV/r. Mild lipoatrophy. History of alcoholism or drug addiction that discourages participation in the study. Pregnancy or breastfeeding. Documented current or 4 weeks prior opportunistic infection. Creatinin clearance &lt; 60mL/min. Concomitant use of nephrotoxic drugs or immunosuppressants. Actual treatment with systemic corticosteroids, IL2 or chemotherapy. Patients under treatment with other drugs in investigation. Acute hepatitis. Any other disease that discourages participation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>HIV - Lipoatrophy</keyword>
	<keyword>treatment experienced</keyword>
</DOC>